Page 46 - CJO_F18

C RECHERCHE CLINIQUE

51. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. hydrochloride 0.1% ophthalmic solution and ketotifen fumarate
A randomized, double-masked, placebo-controlled parallel study 0.025% ophthalmic solution in the conjunctival antigen challenge
of 0.2% loteprednol etabonate in patients with seasonal allergic model. Clin Ther 2000;22:826-33.
conjunctivitis. J Allergy Clin Immunol 1998;102:251-5. 63. Williams JI, Kennedy KS, Gow JA, et al. Prolonged effectiveness BEPREVE™
52. Shulman DG, Lothringer LL, Rubin JM, et coll. A randomized, of bepotastine besilate ophthalmic solution for the treatment of
double-masked, placebo-controlled parallel study of loteprednol ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther (bepotastine besilate ophthalmic solution) 1.5% w/v
etabonate 0.2% in patients with seasonal allergic conjunctivitis. 2011;27:385-93.
Ophthalmology 1999;106:362-9. 64. Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-
53. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G. Clinical term safety of loteprednol etabonate 0.2% in the treatment of
evaluation of ketorolac tromethamine 0.5% ophthalmic solution for seasonal and perennial allergic conjunctivitis. Eye Contact Lens HELP TREAT THE ITCH
the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 2004;30:10-3.
1993;38 Suppl. 141-8. 65. Comstock TL, Sheppard JD. Loteprednol etabonate for in-
54. Bielory L. Update on ocular allergy treatment. Expert Opin Pharma- flammatory conditions of the anterior segment of the eye: 1
cother 2002;3:541-53. Twenty years of clinical experience with a retrometabolically ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
55. Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical designed corticosteroid. Expert Opin Pharmacother 2018. doi:
treatments for seasonal allergic conjunctivitis: systematic review 10.1080/14656566.2018.1439920.
and meta-analysis of efficacy and effectiveness. Br J Gen Pract 66. Tauber J, Raizman MB, Ostrov CS, et coll. A multicenter compari-
2004;54:451-6. son of the ocular efficacy and safety of diclofenac 0.1% solution
1–4,
56. Abelson MB, Berdy GJ, Mundorf T, Amdahl LD, Graves AL, Pemi- with that of ketorolac 0.5% solution in patients with acute seasonal BEPREVE™ demonstrated significant reduction in ocular itching at 3 minutes post CAC *
rolast study g. Pemirolast potassium 0.1% ophthalmic solution is an allergic conjunctivitis. J Ocul Pharmacol Ther 1998;14:137-45.
effective treatment for allergic conjunctivitis: a pooled analysis of 67. Yaylali V, Demirlenk I, Tatlipinar S, et coll. Comparative study of
two prospective, randomized, double-masked, placebo-controlled, 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine Ocular itch scores at 3 minutes post CAC (both eyes averaged)
phase III studies. J Ocul Pharmacol Ther 2002;18:475-88. in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol
57. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Scand 2003 Aug;81(4):378-82.
Surv Ophthalmol 1986;30:229-44. 68. Celik T, Turkoglu EB. Comparative evaluation of olopatadine 0.01% Study A 2,4 Study B 3,4
58. Manzouri B, Flynn TH, Larkin F, Ono SJ, Wyse R. Pharmacotherapy combined fluorometholone 0.1% treatment versus olopatadine
of allergic eye disease. Expert Opin Pharmacother 2006;7:1191-200. 0.01% combined ketorolac 0.4% treatment in patients with acute
59. Leonardi A, Abelson MB. Double-masked, randomized, placebo- seasonal allergic conjunctivitis. Curr Eye Res 2014;39:42-6. 1.87
controlled clinical study of the mast cell-stabilizing effects of treat- 69. Wan KH, Chen LJ, Rong SS, Pang CP, Young AL. Topical cyclospo- 1.85
ment with olopatadine in the conjunctival allergen challenge model rine in the treatment of allergic conjunctivitis: a meta-analysis. 2.00 (n = 36) 2.00
in humans. Clin Ther 2003;25:2539-52. Ophthalmology 2013;120:2197-203. 73.8 % 78.4 % (n = 43)
60. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus 70. Fukushima A, Ohashi Y, Ebihara N, et coll. Therapeutic effects of
ketotifen ophthalmic solutions: a double-masked, environmental 0.1% tacrolimus eye drops for refractory allergic ocular diseases 1.50 1.38 † 1.50 1.45 ‡
study of patient preference. Curr Med Res Opin 2004;20:1167-73. with proliferative lesion or corneal involvement. Br J Ophthalmol
61. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the 2014;98:1023-7.
effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% 71. Moote W, Kim H. Allergen-specific immunotherapy. Allergy,
ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, asthma, and clinical immunology : official journal of the Canadian Ocular itch score 1.00 0.49 Ocular itch score 1.00
randomized, double-masked, artificial tear substitute-controlled Society of Allergy and Clinical Immunology. 2011;7 Suppl. 1:S5. 0.40
trial. Clin Ther 2005;27:1392-402. 72. Berger WE, Granet DB, Kabat AG. Diagnosis and management of (n = 35)
62. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A compar- allergic conjunctivitis in pediatric patients. Allergy Asthma Proc 0.50 0.50 (n = 43)
ison of the relative efficacy and clinical performance of olopatadine 2017;38:16-27.
0.00 0.00
BEPREVE ™ Placebo BEPREVE ™ Placebo
† P <0.001 ‡ P <0.0001
• At Visit 5 (15 minutes after instillation of BEPREVE™ 1.5% w/v), the mean difference in ocular itch score 3 minutes post CAC,
compared to placebo, was 1.4 and 1.5 in Study A 2,4,§ and Study B 3,4,§ , respectively

Indication and clinical use: • BEPREVE™ should not be instilled while wearing contact lenses. BEPREVE™
BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% w/v is indicated for the contains benzalkonium chloride as a preservative, which may be absorbed by soft
treatment of itching associated with allergic conjunctivitis. contact lenses. Remove contact lenses prior to instillation; lenses may be reinserted
• The safety and efficacy of BEPREVE™ has not been established in pediatric patients 10 minutes after the administration of BEPREVE™
under 3 years of age and should not be used in this population • BEPREVE™ should not be used in pregnant women unless the benefit to the mother
• Efficacy of BEPREVE™ in pediatric patients with age <10 was extrapolated from clearly outweighs the risk to the fetus
clinical trials conducted in pediatric patients with age >10 and in adults • Caution should be exercised when BEPREVE™ is administered to lactating women
Relevant warnings and precautions: For more information:
• BEPREVE™ is for topical ophthalmic use only Please consult the Product Monograph at http://www.bausch.ca/Portals/59/Files/
• Do not touch the eyelids or surrounding areas with the dropper tip of bottle and keep Monograph/Pharma/bepreve-pm-en.pdf for important information relating to adverse
bottle tightly closed when not in use reactions, drug interactions, and dosing information that has not been discussed in this
• BEPREVE™ should not be used to treat contact lens–related irritation piece. The Product Monograph is also available by calling 1-888-459-5000.

* CAC = conjunctival allergen challenge
§ Both Studies A and B were phase III, double-masked, randomized, placebo-controlled CAC clinical trials in which patients were assigned to BEPREVE™ or placebo. Analysis used CAC model of allergic
conjunctivitis (i.e., using multiple allergens, both seasonal and perennial). Ocular itching was graded by subjects using a 9-point scale (0–4 U, half units allowed). Primary endpoints included ocular itching with
dose applied bilaterally 15 minutes, 8 hours, and 16 hours prior to challenge (measured 3, 5, and 7 minutes post CAC). 1–4
References: 1. BEPREVE™ (bepotastine besilate ophthalmic solution 1.5%) Product Monograph. Bausch & Lomb Canada Inc.; July 22, 2016. 2. Abelson MB, Torkildsen GL, Williams JI, et al. Time to
onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked,
placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 2009;31:1908–21. 3. Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of
bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol 2010;15:122–7. 4. Data on file, Bausch & Lomb Incorporated, 2008.

46 CANADIAN JOURNAL of OPTOMETRY | REVUE CANADIENNE D’OPTOMÉTRIE VOL. 80 NO. 3
Bausch & Lomb Canada, Vaughan, Ontario L4K 4B4
© Valeant Canada LP
®/ ™ are trademarks of Bausch & Lomb Incorporated or its affiliates.

38668_CJO_F18 August 10, 2018 8:58 AM APPROVAL: ___________________ DATE: ___________________